Potentiation of oncolytic adenoviral vector efficacy with gutless vectors encoding GMCSF or TRAIL
- 19 January 2004
- journal article
- Published by Springer Nature in Cancer Gene Therapy
- Vol. 11 (2) , 92-102
- https://doi.org/10.1038/sj.cgt.7700660
Abstract
No abstract availableKeywords
This publication has 26 references indexed in Scilit:
- Cytolytic viruses as potential anti-cancer agentsJournal of General Virology, 2002
- Gene delivery from the E3 region of replicating human adenovirus: evaluation of the 6.7 K/gp19 K regionGene Therapy, 2001
- Viral Vectors for Gene TransferDrugs, 2000
- Replicative adenoviruses for cancer therapyNature Biotechnology, 2000
- Immune responses to adenoviruses: viral evasion mechanisms and their implications for the clinicCurrent Opinion in Immunology, 1999
- A Novel Tumor-Specific Replication-Restricted Adenoviral Vector for Gene Therapy of Hepatocellular CarcinomaHuman Gene Therapy, 1999
- Cancer Cell CyclesScience, 1996
- An Adenovirus Mutant That Replicates Selectively in p53- Deficient Human Tumor CellsScience, 1996
- Transcriptional control by E2FSeminars in Cancer Biology, 1995
- Cell cycle-regulated transcription in mammalian cellsPublished by Springer Nature ,1995